Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Les Franqueses, Barcelona, 08520, ES
Zhaoke will become the recommended trusted partner for Fareva’s customers who seek to manufacture pharmaceutical products in China.
By: Charlie Sternberg
New advanced labeling product preserves the stability and integrity of light-sensitive medications from packaging to administration, while enabling product visibility.
Creates an independent global specialist CRO in fast-growing markets.
RZL-012 is an injectable treatment for focal fat reduction that is currently progressing toward Phase 3 trials.
Partnership enables seamless integration of an OCI-compliant credential into the rfxcel platform.
Automates routine laboratory experiments previously performed manually.
The two companies will develop and scale production for a novel recombinant version of alpha-1 antitrypsin targeting lung diseases.
By: Rachel Klemovitch
Kane will advance strategic priorities and advance Solrikitug, its lead asset, in Phase II trials and prepare for Phase III.
Will accelerate PCI’s position in the CDMO space.
Partnership will accelerate and broaden access to treatment for more patients with generalized pustular psoriasis, a rare skin condition.
Aim to deliver an advanced, fully tested, fully automated robotically operated CGT manufacturing platform to the market.
The antibody, ISB 2001, is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM).
Aligns with the company’s broader strategy to invest significantly across its global network.
Gilead will supply enough lenacapavir doses to reach up to two million people over three years in countries supported by the Global Fund, at no profit to Gilead.
The Phase 3 study evaluating quemliclustat plus chemotherapy as a first-line treatment for metastatic pancreatic cancer is expected to be fully enrolled by the end of this year.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
